Takeda Pharmaceutical Co Ltd (TKPHF) stock
TKPHFOTCPharmaceutical PreparationsAlso trades as TAK
$39.00+0.36 (+0.93%)
Close on Oct 19, 2026Market cap $134.41BP/E –Yield –
Takeda Pharmaceutical r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2026 it was ¥675.92B, down 7.4% from the year before. The highest annual figure on record is ¥730.23B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | ¥675.92B | -7.4% |
| FY2025 | Mar 31, 2025 | ¥730.23B | +0.0% |
| FY2024 | Mar 31, 2024 | ¥729.92B | +15.3% |
| FY2023 | Mar 31, 2023 | ¥633.33B | +20.4% |
| FY2022 | Mar 31, 2022 | ¥526.09B | +15.4% |
| FY2021 | Mar 31, 2021 | ¥455.83B | -7.4% |
| FY2020 | Mar 31, 2020 | ¥492.38B | +33.7% |
| FY2019 | Mar 31, 2019 | ¥368.30B | +13.2% |
| FY2018 | Mar 31, 2018 | ¥325.44B | +4.2% |
| FY2017 | Mar 31, 2017 | ¥312.30B | – |